Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

NCT04409561 · View on ClinicalTrials.gov ↗

Study Summary

This is a single center, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.

Interventions

  • DEVICE Blood collection

Study Locations (1)

Ohio

  • Mercy Health St. Vincent — Toledo

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2021-11-15
Est. Completion 2022-01-15

Sponsor

Abionic

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04409561

The ClinicalTrials.gov registry entry for NCT04409561 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abionic, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention — of which Blood collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04409561 reports 1 study location spanning 1 distinct geographic area — top geographies include Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04409561 about?

NCT04409561 is a clinical study titled "Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population". This is a single center, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.

What is the current status of trial NCT04409561?

This trial is currently completed. The enrollment target is 150 participants. The study started on 2021-11-15. Estimated completion is 2022-01-15.

What conditions does trial NCT04409561 study?

This clinical trial studies the following conditions: Healthy, Sepsis, Septic Shock. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04409561?

The interventions under investigation include: Blood collection (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04409561?

This trial is sponsored by Abionic, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04409561 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial